These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 24704104)

  • 21. Acceptability of oral liquid pharmaceutical products in older adults: palatability and swallowability issues.
    Belissa E; Vallet T; Laribe-Caget S; Chevallier A; Chedhomme FX; Abdallah F; Bachalat N; Belbachir SA; Boulaich I; Bloch V; Delahaye A; Depoisson M; Wojcicki AD; Gibaud S; Grancher AS; Guinot C; Lachuer C; Lechowski L; Leglise P; Mahiou A; Meaume S; Michel C; Michelon H; Orven Y; Perquy I; Piccoli M; Rabus M; Ribemont AC; Rwabihama JP; Trouvin JH; Ruiz F; Boudy V
    BMC Geriatr; 2019 Dec; 19(1):344. PubMed ID: 31810442
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Pediatric formulations: international issues and potential solutions.
    Knoppert DC
    Paediatr Drugs; 2009; 11(1):55-6. PubMed ID: 19127956
    [TBL] [Abstract][Full Text] [Related]  

  • 23. PBPK models for the prediction of in vivo performance of oral dosage forms.
    Kostewicz ES; Aarons L; Bergstrand M; Bolger MB; Galetin A; Hatley O; Jamei M; Lloyd R; Pepin X; Rostami-Hodjegan A; Sjögren E; Tannergren C; Turner DB; Wagner C; Weitschies W; Dressman J
    Eur J Pharm Sci; 2014 Jun; 57():300-21. PubMed ID: 24060672
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Pharmaceutical manufacturers and unit-dose packaging.
    Miller RW
    Am J Hosp Pharm; 1967 Feb; 24(2):76-8. PubMed ID: 6040684
    [No Abstract]   [Full Text] [Related]  

  • 25. Taste-masking assessment of solid oral dosage forms--a critical review.
    Pein M; Preis M; Eckert C; Kiene FE
    Int J Pharm; 2014 Apr; 465(1-2):239-54. PubMed ID: 24509066
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Current administration practices and preferred formulations of children's medicines in Tanzania: summary of survey findings.
    Adams LV; Craig SR; Mmbaga EJ; Naburi H; Lahey T; Kisenge R; Spielberg SP
    Int J Pharm; 2012 Oct; 435(2):150-1. PubMed ID: 22883704
    [No Abstract]   [Full Text] [Related]  

  • 27. Biorelevant in-vitro performance testing of orally administered dosage forms.
    Reppas C; Vertzoni M
    J Pharm Pharmacol; 2012 Jul; 64(7):919-30. PubMed ID: 22686340
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Dosage form suitability in vulnerable populations: A focus on paracetamol acceptability from infants to centenarians.
    Ruiz F; Vallet T; Dufaÿ Wojcicki A; Belissa É; Fontan JE; de Pontual L; Nathanson S; Chevallier A; Laribe-Caget S; Boudy V
    PLoS One; 2019; 14(8):e0221261. PubMed ID: 31430323
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Problems posed by the adjusting of a dosage form of a drug for children].
    Bernheim C
    Therapie; 1989; 44(2):145-50. PubMed ID: 2756521
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Taste-masking possibilities in solid dosage forms].
    Szakonyi G; Zelkó R
    Acta Pharm Hung; 2012; 82(2):81-90. PubMed ID: 22870781
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Optimization of pediatric medication].
    Gafiţanu E; Matei J; Vasiliu I
    Rev Med Chir Soc Med Nat Iasi; 1986; 90(1):149-52. PubMed ID: 3764165
    [No Abstract]   [Full Text] [Related]  

  • 32. Orally disintegrating dosage forms and taste-masking technologies; 2010.
    Douroumis D
    Expert Opin Drug Deliv; 2011 May; 8(5):665-75. PubMed ID: 21438776
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Drug development for children: how is pharma tackling an unmet need?
    Hawcutt DB; Smyth RL
    IDrugs; 2008 Jul; 11(7):502-7. PubMed ID: 18600597
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Is there a need for a universal benefit-risk assessment framework for medicines? Regulatory and industry perspectives.
    Leong J; McAuslane N; Walker S; Salek S
    Pharmacoepidemiol Drug Saf; 2013 Sep; 22(9):1004-12. PubMed ID: 23740622
    [TBL] [Abstract][Full Text] [Related]  

  • 35. FDA: contribution to developing pediatric formulations and transatlantic collaboration.
    Khan MA; Wu K; Gupta A
    Int J Pharm; 2012 Oct; 435(2):146-8. PubMed ID: 22883702
    [No Abstract]   [Full Text] [Related]  

  • 36. Basics of compounding foam dosage forms.
    Allen LV
    Int J Pharm Compd; 2013; 17(4):312-22. PubMed ID: 24261147
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Guidelines for single-unit packages of drugs approved by the Board of Directors, American Society of Hospital Pharmacists December 2, 1966.
    Am J Hosp Pharm; 1967 Feb; 24(2):79-80. PubMed ID: 6040685
    [No Abstract]   [Full Text] [Related]  

  • 38. [How can we make drug taking easier for children?].
    Hultzsch W
    Med Monatsschr Pharm; 2005 Jul; 28(7):243. PubMed ID: 16038122
    [No Abstract]   [Full Text] [Related]  

  • 39. How do Japanese children take their medicines, and what are pharmacists and paediatricians doing about it?
    Nakamura H; Ishikawa Y
    Int J Pharm; 2014 Aug; 469(2):249-50. PubMed ID: 24704105
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Oral drug delivery in personalized medicine: unmet needs and novel approaches.
    Wening K; Breitkreutz J
    Int J Pharm; 2011 Feb; 404(1-2):1-9. PubMed ID: 21070842
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.